Vijay Raina is a titan in the world of enterprise SaaS, bringing years of architectural insight and a clinical eye for software design to the complex world of supply chain technology. As the industry navigates a period of rapid digital transformation, Vijay has become a go-to voice for understanding how legacy systems are being dismantled in favor of agile, cloud-native platforms that can handle the sheer volume of modern logistical data. Our conversation centers on the remarkable fiscal performance of Tecsys, a company that has recently shattered its own records and provided a masterclass in how to pivot from a migration-heavy strategy to one focused on deep customer expansion and artificial intelligence integration. Throughout our discussion, we explore the nuances of the healthcare supply chain, the technical hurdles of FedRAMP certification, and why the “data exhaust” of warehouse management is suddenly the most valuable asset a hospital can own.
We are seeing a profound shift where existing healthcare customers are increasingly deepening their use of supply chain platforms rather than just maintaining legacy systems. How is this changing the value proposition for enterprise software providers?
The shift we are witnessing is less about maintenance and more about total operational immersion. For a long time, hospitals looked at supply chain software as a necessary back-office burden—a way to track boxes in a basement. Today, that mindset has been completely upended because the financial pressure on these institutions is immense, with labor costs and reimbursement cuts squeezing margins to the breaking point. Major health systems like Prisma Health are no longer content with just a warehouse or pharmacy module; they are expanding their footprint into point-of-use technology across their entire networks to gain visibility for 1.6 million patients. When a provider moves from legacy systems to a platform like Tecsys Elite, they aren’t just buying a tool; they are investing in a nervous system that connects clinical needs to supply chain reality. This expansion activity was the heartbeat of the most recent quarter, driving a staggering 24% year-over-year growth in Elite SaaS revenue, as hospitals realized that fragmented legacy tools simply cannot provide the end-to-end visibility required to survive in 2026.
Tecsys recently reported its second-highest bookings quarter in company history during a period that is traditionally considered seasonally weak. What does this tell us about the current urgency within the healthcare market?
It is highly unusual to see record-breaking numbers in a first quarter that ends in July, primarily because the “summer slump” usually hits as executives head out on vacation. However, the fact that total revenue reached CAD 50.0 million—a 9% increase—suggests that the “lumpiness” we often talk about in enterprise sales is being smoothed out by sheer necessity. Hospitals are facing a demographic time bomb with an aging population, and they have reached a point where they can no longer “wait and see” before fixing their supply chain leaks. We are seeing a real sense of urgency because the ROI studies are becoming undeniable; when a sales team can walk into a boardroom and show a hospital they can save CAD 200 million over five years, the deal moves to the top of the priority list regardless of the season. This urgency is reflected in the Remaining Performance Obligations (RPO), which crossed the CAD 250 million threshold for the first time, landing at CAD 259.2 million, which provides a massive amount of forward visibility and stability that just didn’t exist a few years ago.
There is a lot of talk about TecsysIQ and the role of artificial intelligence in supply chain management. How central has AI become to the actual sales process and the decision-making of Chief Information Officers?
The most striking takeaway from the recent executive commentary is that virtually no one is buying the latest platform without also purchasing TecsysIQ. We’ve moved past the phase where AI was a flashy “add-on” or a future roadmap item; it is now the primary driver of the entire conversation. CIOs are realizing that they have been sitting on years of “information exhaust”—data about every millisecond of movement in their warehouses—and they finally have the tools to turn that data into labor-efficiency gains. By utilizing a chat interface or an AI-driven dashboard, a head of surgery can now ask the system if a pending shortage will impact tomorrow’s scheduled procedures and get an immediate, data-backed answer. This level of sophistication is why expansion bookings are coming in with gross margins of 80% or higher, as the incremental cost of adding these intelligent layers is minimal compared to the massive value they unlock for the customer.
The financial results showed a massive 90.91% positive surprise in earnings per share. What specific levers did the company pull to convert revenue growth into such a significant profit jump?
A 306% jump in net profit to CAD 3.1 million is the kind of number that makes the market sit up and take notice, and it’s a direct result of disciplined operating leverage and a shift in the revenue mix. As the company moves away from lower-margin legacy business and professional services, which saw some sequential softening, the high-margin SaaS revenue is starting to do the heavy lifting. The adjusted EBITDA margin hit 13.7% in the first quarter, which is right at the top of their revised full-year range, showing that they are getting much better at scaling without a linear increase in costs. You also have to look at the “land and expand” strategy; it is significantly cheaper to sell additional modules to an existing partner like UT Southwestern Medical Center than it is to hunt for a completely new logo. This efficiency, combined with the fact that they ended the quarter with CAD 35 million in cash and zero debt, puts them in a very powerful position to reinvest in hiring and R&D without diluting their earnings power.
Looking at the public sector, the company mentioned they are currently navigating the FedRAMP certification process. Why is this specific milestone so critical for a software provider in the current landscape?
FedRAMP is essentially the gold standard for security and process documentation, and achieving it is like receiving a “key to the city” for both government and high-security enterprise contracts. The process is grueling—Tecsys has already produced a 900-page document covering nearly 500 different security processes—but once you are in that “auditor review” phase, you are on the home stretch toward full certification. For the public sector, this is a non-negotiable requirement, but even for private hospital networks, seeing that a provider has cleared the FedRAMP hurdle provides a massive amount of peace of mind regarding data integrity and cyber resilience. They are expecting to wrap this up by late winter or early spring 2027, and once that happens, it opens up a multi-billion dollar Total Addressable Market (TAM) in the U.S. government space that has been largely insulated from the typical competitive pressures of the private market.
The professional services segment experienced some lighter bookings this quarter, which management noted might lead to a sequential dip. Is this a sign of trouble, or just a natural evolution of the SaaS business model?
It’s actually a classic example of the “timing lag” that occurs in high-growth SaaS companies where the software booking happens instantly, but the implementation work follows a few months later. When you have a record-breaking SaaS booking quarter, the professional services team is often busy in the “planning and charter” phase, which doesn’t always show up as immediate revenue. The backlog might tick down temporarily, but with a number of project charters currently being finalized for those Q4 and Q1 wins, we should see those teams at full capacity again very quickly. Furthermore, we’re seeing a shift toward partner-led implementations, which is actually a healthy sign for a maturing ecosystem. If third-party firms are handling more of the heavy lifting for deployments, Tecsys can keep its internal headcount leaner and focus on the high-margin recurring revenue that investors crave.
We’ve seen the OrderDynamics retail business shrink from 10% of ARR down to less than 5% in a single year. How does shedding this non-core legacy business help the company’s long-term focus?
It’s all about removing the “noise” so that the market can see the true strength of the core Elite platform. For several quarters, the impressive growth in healthcare was being partially masked by the intentional churn of these older retail accounts that no longer fit the company’s strategic vision. By the end of this fiscal year, that segment will be a negligible part of the business, which means the “drag” on overall ARR growth will disappear. This allows management to be “all in” on healthcare and complex distribution, where they have a clear competitive advantage and significantly higher customer retention rates. Investors are already beginning to see this, as the Elite SaaS ARR grew by 24% this quarter, providing a much cleaner and more exciting narrative for the company’s trajectory heading into the second half of the year.
What is your forecast for the healthcare supply chain sector over the next twelve to eighteen months?
I expect we are going to see a “great consolidation” of data where the physical world of hospital supplies finally becomes as digital and searchable as a financial ledger. Over the next year and a half, the pressure of declining reimbursements will force even the most conservative hospital boards to adopt AI-driven supply chain platforms, as it will be the only way to find the CAD 20 million to CAD 50 million in annual savings needed to keep their doors open. We will likely see Tecsys continue to exceed its raised guidance, particularly as the FedRAMP certification lands and the TecsysIQ platform matures from a predictive tool into an autonomous one. The “lumpiness” of the past will give way to a more predictable, high-margin growth engine, and by the time we reach the end of fiscal 2027, the conversation will have shifted entirely from “how do we track supplies” to “how do we use our supply chain as a strategic weapon for patient care.”
